Roivant Sciences Ltd. (ROIV) income statement
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.73+0.02 (+0.05%)
Close on Nov 18, 2026Market cap $27.98BP/E –Yield –
Roivant Sciences Ltd. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -7914.8%
- Net margin
- -3535.0%
- Return on equity, FY2025
- -6.5%
Financial strength
- Current ratio
- 16.72
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 440.2%
Valuation
- P/E ratio
- –
- Price to sales
- 3714.23
- Price to book
- 6.61
- Dividend yield
- –
See a number that looks wrong?